Open Orphan (ORPH) on Monday announced that five pharmaceutical and biotechnology companies have signed on as early adopters of its Genomic Health DataBANK platform.
The platform, which aims to establish a rare disease database, is expected to roll out in Q1 of 2020.
Maurice Treacy, Chief Commercial Officer of Open Orphan commented: "We are very excited to be working with these leading pharmaceutical and biotechnology companies on our market leading DataBANK.”
The five companies signed up to the platform will make sure the database is “fit-for-purpose” for pharmaceutical and data analysis purposes.
Shares in Open Orphan ticked up 1.6% to 6.35p during Monday morning trading
Mr. Treacy told investors: “The Genomic Health DataBANK, which makes extensive use of AI tools, is an innovative research tool for pharmaceutical companies, and we are excited by its potential when launched in early 2020.”
He added: “We believe the DataBANK can ignite research for new diagnostic tools and therapeutic products for rare disease patients."
Open Orphan also told investors it is working to finalize early adopter agreements with several Patient Advocacy Groups to make their patients aware of the platform and sign on.
Follow News & Updates from Open Orphan here: